Drug intelligence / Profile preview

WIT-2001

Development stage: Unknown
Lead developer: WhanIn Pharm
Modality: Small Molecules

Overview

WIT-2001 is a small molecule drug candidate being developed by Whanin Pharmaceutical for the treatment of Parkinson's disease. Currently in Phase 1 clinical development, the compound is part of the company's research focus on nervous system and metabolic diseases. Specific details regarding its molecular target and mechanism of action are not yet publicly available, though it is positioned within the company's R&D pipeline for neurodegenerative conditions.

Beyond the preview

Go deeper on WIT-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WIT-2001.

Explore the full profile